Tags

Type your tag names separated by a space and hit enter

The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
J Psychiatr Pract. 2010 Sep; 16(5):289-96.JP

Abstract

Patients with schizophrenia have a greater incidence of being overweight or obese compared with the general population. Such individuals are often treated with second-generation (atypical) antipsychotics (SGAs), which are associated with weight gain, dyslipidemia, and other metabolic derangements. As a result, frequent monitoring of weight and other metabolic parameters is recommended. In addition, several pharmacologic strategies to help prevent or reduce SGA-induced weight gain have been proposed. Despite this, clinicians often struggle to manage obesity and metabolic issues in such patients. Metformin has attracted attention as a potential treatment option because it is thought to result in weight reduction and improved glycemic control in obese patients with and without type 2 diabetes mellitus. This article focuses on relevant pharmacologic aspects of metformin and reviews currently available evidence on the use of metformin as an augmentation agent for the treatment or prevention of SGA-induced weight gain.

Authors+Show Affiliations

University of Kansas School of Medicine-Wichita †Via Christi Regional Medical Center, Wichita, KS 67214, USA. akhan@kumc.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20859106

Citation

Khan, Ahsan Y., et al. "The Adjunctive Use of Metformin to Treat or Prevent Atypical Antipsychotic-induced Weight Gain: a Review." Journal of Psychiatric Practice, vol. 16, no. 5, 2010, pp. 289-96.
Khan AY, Macaluso M, McHale RJ, et al. The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. J Psychiatr Pract. 2010;16(5):289-96.
Khan, A. Y., Macaluso, M., McHale, R. J., Dahmen, M. M., Girrens, K., & Ali, F. (2010). The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. Journal of Psychiatric Practice, 16(5), 289-96. https://doi.org/10.1097/01.pra.0000388624.91039.a3
Khan AY, et al. The Adjunctive Use of Metformin to Treat or Prevent Atypical Antipsychotic-induced Weight Gain: a Review. J Psychiatr Pract. 2010;16(5):289-96. PubMed PMID: 20859106.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. AU - Khan,Ahsan Y, AU - Macaluso,Matthew, AU - McHale,Robert J, AU - Dahmen,Megan M, AU - Girrens,Kathrine, AU - Ali,Faryal, PY - 2010/9/23/entrez PY - 2010/9/23/pubmed PY - 2011/2/3/medline SP - 289 EP - 96 JF - Journal of psychiatric practice JO - J Psychiatr Pract VL - 16 IS - 5 N2 - Patients with schizophrenia have a greater incidence of being overweight or obese compared with the general population. Such individuals are often treated with second-generation (atypical) antipsychotics (SGAs), which are associated with weight gain, dyslipidemia, and other metabolic derangements. As a result, frequent monitoring of weight and other metabolic parameters is recommended. In addition, several pharmacologic strategies to help prevent or reduce SGA-induced weight gain have been proposed. Despite this, clinicians often struggle to manage obesity and metabolic issues in such patients. Metformin has attracted attention as a potential treatment option because it is thought to result in weight reduction and improved glycemic control in obese patients with and without type 2 diabetes mellitus. This article focuses on relevant pharmacologic aspects of metformin and reviews currently available evidence on the use of metformin as an augmentation agent for the treatment or prevention of SGA-induced weight gain. SN - 1538-1145 UR - https://www.unboundmedicine.com/medline/citation/20859106/The_adjunctive_use_of_metformin_to_treat_or_prevent_atypical_antipsychotic_induced_weight_gain:_a_review_ L2 - https://doi.org/10.1097/01.pra.0000388624.91039.a3 DB - PRIME DP - Unbound Medicine ER -